CannaMetrix’s proprietary, high-throughput human-cell based assay technology can show exactly how the components in each strain affect cannabinoid signalling in human cells. This information will inform the design of new plant strains with bespoke profiles to improve patient and consumer outcomes. 

KeyGene utilizes its expertise in bioinformatics, genetic engineering, and molecular breeding to help us develop new plant lines with traits we desire. In essence, KeyGene helps to provide us with the exact genetic information associated with given traits and the knowledge to precisely alter or enhance these traits in a genome to create a specific result.

Breeding and trials are conducted with multiple global partners, such as Extractas Bioscience, to field test and select the new strains. These partners use their knowledge of plant structure and agronomics to select plants that are easier to grow and harvest.

We’ve engaged researchers at several universities on a fee basis. Those at North Carolina State University are assisting us with tobacco. Scientists at the University of Tennessee and the University of Kentucky are collaborating with us in testing tobacco and cannabis

Finally, our newly acquired subsidiary, GVB Biopharma, provides the scalable production, extraction, and packaging of valuable cannabinoids for bulk and specialty markets. This manufacturing capacity is crucial to delivering on the promise of all our research.